Fradet-Aubignat (pictured) has been based in the UK with Research Partnership for more than five years and has experience of working with many of the global pharmaceutical companies based in France. She will have a remit to grow and expand the Lyon office, as well as to service existing clients based in France, Switzerland and Germany.

A native French speaker, Fradet-Aubignat conducts both qualitative and quantitative studies across a wide range of therapy areas with particular interest in oncology, vaccines and cardiovascular diseases.

Founding director Mark Jeffery said: “This demonstrates our on-going commitment to servicing the European market. Having an office in France supports our long-term objectives to expand and grow the business in Europe and we hope to make announcements of further expansion in 2018 and beyond.”